US20090011047A1 - Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment or urogenital cancer and its metastasis - Google Patents

Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment or urogenital cancer and its metastasis Download PDF

Info

Publication number
US20090011047A1
US20090011047A1 US11/631,962 US63196206A US2009011047A1 US 20090011047 A1 US20090011047 A1 US 20090011047A1 US 63196206 A US63196206 A US 63196206A US 2009011047 A1 US2009011047 A1 US 2009011047A1
Authority
US
United States
Prior art keywords
cancer
carcinoma
patient
sodium salt
arsenous acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/631,962
Other languages
English (en)
Inventor
Bernardus Rademaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOMINOX Inc
Original Assignee
KOMIPHARM INTERNATIONAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOMIPHARM INTERNATIONAL CO Ltd filed Critical KOMIPHARM INTERNATIONAL CO Ltd
Assigned to KOMIPHARM INTERNATIONAL CO., LTD. reassignment KOMIPHARM INTERNATIONAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RADEMAKER, BERNADUS
Assigned to KOMIPHARM INTERNATIONAL CO., LTD reassignment KOMIPHARM INTERNATIONAL CO., LTD CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR NAME PREVIOUSLY RECORDED ON REEL 021513 FRAME 0396. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: RADEMAKER, BERNARDUS
Publication of US20090011047A1 publication Critical patent/US20090011047A1/en
Assigned to KOMINOX, INC. reassignment KOMINOX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KOMIPHARM INTERNATIONAL CO., LTD.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
US11/631,962 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment or urogenital cancer and its metastasis Abandoned US20090011047A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05076071.9 2005-05-09
EP05076071A EP1721615A1 (en) 2005-05-09 2005-05-09 Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
PCT/KR2006/001731 WO2006121280A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2006/001731 A-371-Of-International WO2006121280A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/077,373 Division US11464859B2 (en) 2005-05-09 2016-03-22 Pharmaceutical compositions comprising sodium meta arsenite for treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
US20090011047A1 true US20090011047A1 (en) 2009-01-08

Family

ID=35197739

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/631,962 Abandoned US20090011047A1 (en) 2005-05-09 2006-05-09 Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment or urogenital cancer and its metastasis
US15/077,373 Active US11464859B2 (en) 2005-05-09 2016-03-22 Pharmaceutical compositions comprising sodium meta arsenite for treatment of multiple myeloma

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/077,373 Active US11464859B2 (en) 2005-05-09 2016-03-22 Pharmaceutical compositions comprising sodium meta arsenite for treatment of multiple myeloma

Country Status (24)

Country Link
US (2) US20090011047A1 (ja)
EP (5) EP1721615A1 (ja)
JP (1) JP5026408B2 (ja)
KR (3) KR20160035101A (ja)
CN (2) CN101277707A (ja)
AR (1) AR054448A1 (ja)
AU (1) AU2006244767B2 (ja)
BR (1) BRPI0608716A2 (ja)
CA (3) CA2926846C (ja)
CY (2) CY1113475T1 (ja)
DK (2) DK1885380T3 (ja)
ES (2) ES2754372T3 (ja)
HK (1) HK1109736A1 (ja)
HU (1) HUE046029T2 (ja)
IL (3) IL187220A (ja)
LT (1) LT3067068T (ja)
PL (2) PL3067068T3 (ja)
PT (1) PT1885380E (ja)
RU (1) RU2401662C2 (ja)
SG (5) SG10201405278SA (ja)
SI (2) SI3067068T1 (ja)
TW (5) TWI386214B (ja)
WO (1) WO2006121280A1 (ja)
ZA (1) ZA200710559B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059186A1 (en) * 2009-09-10 2011-03-10 Kominox Usa, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
US20110070314A1 (en) * 2009-09-18 2011-03-24 Yong Joon Jo Methods for treating brain tumors
US20170340694A1 (en) * 2016-05-26 2017-11-30 Stephen N. Pitcher Composition for promoting metallothionein production
US11464859B2 (en) 2005-05-09 2022-10-11 Kominox, Inc. Pharmaceutical compositions comprising sodium meta arsenite for treatment of multiple myeloma

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20120045520A1 (en) * 2008-08-21 2012-02-23 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
US8735171B2 (en) 2010-01-13 2014-05-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Promyelocytic leukemia protein as a redox sensor
BR112013017499A2 (pt) * 2011-01-11 2016-09-27 Univ Basel combinação de sirosingopina e inibidores mitocondriais para o tratamento de câncer e imunossupressão
WO2012131487A2 (en) * 2011-03-30 2012-10-04 Kominox, Inc. Compositions and methods for the treatment of cancer
KR101309844B1 (ko) * 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
RU2618405C1 (ru) * 2015-12-31 2017-05-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ определения продолжительности адъювантной химиотерапии при местно-распространенном колоректальном раке с метастазами в регионарные лимфоузлы после радикальных оперативных вмешательств
IL265986B (en) 2016-12-01 2022-09-01 Eupharma Pty Ltd A drug compound that includes an alkali metal and/or an alkaline metal oxide tetraoxide (iii) and its uses
MA52088A (fr) * 2018-03-22 2021-01-27 Komipharm Int Australia Pty Ltd Composition pharmaceutique comprenant du méta-arsénite et procédé de fabrication
WO2019234112A1 (en) * 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
JOP20220192A1 (ar) * 2020-02-16 2023-01-30 Panaphix Inc طريقة علاج باستخدام ميتا-الزرنيخ
KR20220020635A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 외용제 조성물
KR20220020633A (ko) * 2020-08-12 2022-02-21 이상봉 탈모방지 또는 발모촉진용 주사제 조성물
KR20220020637A (ko) * 2020-08-12 2022-02-21 이상봉 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물
CN112336746A (zh) * 2020-10-23 2021-02-09 内蒙古科技大学包头医学院 一种膀胱癌灌注化疗药物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889048A (en) * 1994-02-18 1999-03-30 Vorobieva; Tamara Vasilievna Methods and compositions for treating defective cell functions
US20020183385A1 (en) * 1997-10-15 2002-12-05 Ellison Ralph M. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
FR2431686A1 (fr) 1978-07-20 1980-02-15 Nestle Sa Soc Ass Tech Prod Mecanisme de dosage et d'equilibrage et machine de remplissage comprenant un tel mecanisme
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
KR930001917A (ko) * 1991-07-26 1993-02-22 김두석 악성 종양 치료제의 제조방법
US6770304B2 (en) 1997-11-10 2004-08-03 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
WO2003086424A1 (en) * 2002-04-10 2003-10-23 Korea Microbiological Laboratories, Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
KR100632250B1 (ko) * 2004-02-16 2006-10-11 정태호 비소 화합물을 유효성분으로 하는 항암제
US20060104292A1 (en) 2004-11-15 2006-05-18 Gupta Vivek G System and methods for supporting multiple communications interfaces with single client interface
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
CN102753164A (zh) 2009-09-10 2012-10-24 柯密纳克斯公司 靶向癌症干细胞的耐药性癌症疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889048A (en) * 1994-02-18 1999-03-30 Vorobieva; Tamara Vasilievna Methods and compositions for treating defective cell functions
US20020183385A1 (en) * 1997-10-15 2002-12-05 Ellison Ralph M. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lee et al. KR-20020083458 Machine English translation provided. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464859B2 (en) 2005-05-09 2022-10-11 Kominox, Inc. Pharmaceutical compositions comprising sodium meta arsenite for treatment of multiple myeloma
US20110059186A1 (en) * 2009-09-10 2011-03-10 Kominox Usa, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
WO2011031890A3 (en) * 2009-09-10 2011-08-25 Kominox, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
JP2013504587A (ja) * 2009-09-10 2013-02-07 コミノックス・インコーポレイテッド 癌幹細胞を標的とした薬剤耐性癌治療法
KR20150038702A (ko) * 2009-09-10 2015-04-08 코미녹스 인코포레이티드 암 줄기세포-표적 및 약물 내성 암 치료
KR101721009B1 (ko) * 2009-09-10 2017-03-29 코미녹스 인코포레이티드 암 줄기세포-표적 및 약물 내성 암 치료
US20110070314A1 (en) * 2009-09-18 2011-03-24 Yong Joon Jo Methods for treating brain tumors
WO2011034775A3 (en) * 2009-09-18 2011-10-06 Kominox, Inc. Methods for treating brain tumors
CN102753188A (zh) * 2009-09-18 2012-10-24 柯密纳克斯公司 治疗脑瘤的方法
US20170340694A1 (en) * 2016-05-26 2017-11-30 Stephen N. Pitcher Composition for promoting metallothionein production
US10806768B2 (en) * 2016-05-26 2020-10-20 Stephen N. Pitcher Composition for promoting metallothionein production

Also Published As

Publication number Publication date
IL187220A (en) 2014-11-30
IL229975A0 (en) 2014-01-30
DK3067068T3 (da) 2019-11-18
EP2361628A1 (en) 2011-08-31
AU2006244767B2 (en) 2011-06-16
SG10201405278SA (en) 2015-05-28
RU2401662C2 (ru) 2010-10-20
PL1885380T3 (pl) 2013-02-28
ES2754372T3 (es) 2020-04-17
AR054448A1 (es) 2007-06-27
SG10201602555WA (en) 2016-05-30
TWI522105B (zh) 2016-02-21
CA2608035A1 (en) 2006-11-16
ES2394264T3 (es) 2013-01-30
CA2840609A1 (en) 2006-11-16
HK1109736A1 (en) 2008-06-20
EP1885380B1 (en) 2012-07-11
IL187220A0 (en) 2008-02-09
CA2840609C (en) 2016-08-16
LT3067068T (lt) 2019-12-10
TW201302208A (zh) 2013-01-16
US20160199411A1 (en) 2016-07-14
KR20150085122A (ko) 2015-07-22
JP5026408B2 (ja) 2012-09-12
ZA200710559B (en) 2008-10-29
CA2926846C (en) 2019-04-02
PT1885380E (pt) 2012-10-11
TW201540306A (zh) 2015-11-01
EP1885380A1 (en) 2008-02-13
SG177983A1 (en) 2012-02-28
EP3067068B1 (en) 2019-08-14
SG10202100785PA (en) 2021-02-25
SI1885380T1 (sl) 2013-01-31
AU2006244767A1 (en) 2006-11-16
SI3067068T1 (sl) 2020-02-28
KR20080030559A (ko) 2008-04-04
KR101413731B1 (ko) 2014-07-10
RU2007145489A (ru) 2009-06-20
WO2006121280A1 (en) 2006-11-16
EP1721615A1 (en) 2006-11-15
IL229975A (en) 2017-12-31
JP2008546640A (ja) 2008-12-25
CN104758312A (zh) 2015-07-08
SG175633A1 (en) 2011-11-28
PL3067068T3 (pl) 2020-08-10
TWI386214B (zh) 2013-02-21
CA2926846A1 (en) 2006-11-16
US11464859B2 (en) 2022-10-11
CY1113475T1 (el) 2016-06-22
HUE046029T2 (hu) 2020-01-28
TW201500046A (zh) 2015-01-01
CA2608035C (en) 2015-02-17
TWI539957B (zh) 2016-07-01
TW200716144A (en) 2007-05-01
BRPI0608716A2 (pt) 2010-12-07
EP2762145A1 (en) 2014-08-06
EP3067068A1 (en) 2016-09-14
DK1885380T3 (da) 2012-10-22
TW201615200A (zh) 2016-05-01
TWI574692B (zh) 2017-03-21
CY1122522T1 (el) 2021-01-27
KR20160035101A (ko) 2016-03-30
CN101277707A (zh) 2008-10-01
IL244728A0 (en) 2016-04-21
EP1885380A4 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
US11464859B2 (en) Pharmaceutical compositions comprising sodium meta arsenite for treatment of multiple myeloma
EP1765328B1 (en) Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
AU2011224052A1 (en) Pharmaceutical compositions comprising of arsenous acid, its sodium salt and its derivatives intended for the treatment of urogenital cancer and its metastasis
KR20140033522A (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물
WO2005062810A2 (en) Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide

Legal Events

Date Code Title Description
AS Assignment

Owner name: KOMIPHARM INTERNATIONAL CO., LTD., KOREA, REPUBLIC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RADEMAKER, BERNADUS;REEL/FRAME:021513/0396

Effective date: 20080131

AS Assignment

Owner name: KOMIPHARM INTERNATIONAL CO., LTD, KOREA, REPUBLIC

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR NAME PREVIOUSLY RECORDED ON REEL 021513 FRAME 0396;ASSIGNOR:RADEMAKER, BERNARDUS;REEL/FRAME:021788/0265

Effective date: 20080131

Owner name: KOMIPHARM INTERNATIONAL CO., LTD, KOREA, REPUBLIC

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR NAME PREVIOUSLY RECORDED ON REEL 021513 FRAME 0396. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:RADEMAKER, BERNARDUS;REEL/FRAME:021788/0265

Effective date: 20080131

AS Assignment

Owner name: KOMINOX, INC., CAYMAN ISLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOMIPHARM INTERNATIONAL CO., LTD.;REEL/FRAME:026766/0675

Effective date: 20090805

AS Assignment

Owner name: KOMINOX, INC., CAYMAN ISLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOMIPHARM INTERNATIONAL CO., LTD.;REEL/FRAME:026742/0487

Effective date: 20090805

XAS Not any more in us assignment database

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOMIPHARM INTERNATIONAL CO., LTD.;REEL/FRAME:026742/0487

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION